Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / Moderna Merck mRNA melanoma vaccine...
Tech clinical trial

Moderna Merck mRNA melanoma vaccine trial success

Analysis based on 102 articles · First reported Aug 19, 2026 · Last updated Aug 20, 2026

Sentiment
85
Attention
8
Articles
102
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The positive trial results triggered a surge in Moderna's stock, which more than doubled, and boosted Merck's shares, reflecting investor optimism about the new cancer treatment. The news also lifted the broader biotech sector, with the Sana Biotechnology reaching a record high, and is expected to drive significant future revenue for both companies.

Biotechnology Pharmaceuticals Healthcare
Event Summary

Moderna and Merck & Co. announced on August 19, 2026, that their personalized mRNA cancer vaccine, Intismeran, combined with Merck's immunotherapy drug Pembrolizumab, met its primary and secondary goals in a Phase 3 trial for high-risk melanoma. The trial enrolled 1,137 patients with stage IIB-IV melanoma who had undergone surgery. The combination significantly improved recurrence-free survival and distant metastasis-free survival compared to Pembrolizumab alone. This is the first positive late-stage trial for an mRNA cancer vaccine. The companies plan to present full data at an upcoming medical meeting and discuss regulatory filings. Moderna's shares surged over 120%, adding nearly $40 billion to its market cap, while Merck's shares rose about 11%. The results validate mRNA technology for cancer treatment and could lead to approval as early as 2027. The companies are also testing the vaccine in lung, bladder, kidney, pancreatic, and other cancers. Analysts project potential annual sales of about $3 billion for melanoma by 2035. The trial is ongoing to assess overall survival.

Key Actions
100 Moderna announced trial results
100 Merck Group announced trial results
100 Merck & Co. announced trial results
96 Marvell Technology issued warrant Alphabet Inc.
90 Merck & Co. saw shares rise
90 Merck Group partnered with Moderna
90 Moderna partnered with Merck Group
85 United States — United States Department of the Treasury doubled buyback sizes
83 Moderna surged in trading
83 Merck Group gained in trading
80 Moderna plans to file for approval United States — Food and Drug Administration
80 Merck & Co. plans to file for approval United States — Food and Drug Administration
80 Moderna developed vaccine
80 Merck Group saw shares rise
80 Merck Group plans to file for approval United States — Food and Drug Administration
+ 21 more actions View on Dashboard
Entities Involved
stock
Moderna
Moderna is the developer of the mRNA vaccine and the primary beneficiary, with its stock surging over 120% and market cap increasing by nearly $40 billion. The trial success validates its mRNA platform beyond COVID-19 and could lead to a new revenue stream.
Importance 100.0 Sentiment 95.0
stock
Merck & Co.
Merck is the partner in developing the vaccine and provides Pembrolizumab, which is combined with the vaccine. The trial success offers a new growth avenue as Pembrolizumab faces patent expiration, and its stock rose about 11%.
Importance 100.0 Sentiment 90.0
stock
Merck Group
Merck co-developed the vaccine and provided Pembrolizumab, the combination partner. Its shares rose about 10-12%, and the success helps Merck prepare for Pembrolizumab's patent expiration by expanding its cancer portfolio.
Importance 95.0 Sentiment 85.0
oth
Intismeran
Intismeran is the personalized mRNA vaccine that met trial endpoints; it is a potential blockbuster and key to Moderna's diversification.
Importance 85.0 Sentiment 85.0
per
Stéphane Bancel
As CEO of Moderna, Bancel announced the results and highlighted the milestone. His leadership is central to the company's strategic direction and investor confidence.
Importance 70.0 Sentiment 80.0
per
Stephen Hoge
As President of Moderna, Hoge provided details on the trial and potential approval timeline, reinforcing the company's optimistic outlook.
Importance 60.0 Sentiment 75.0
govactor
United States — Food and Drug Administration
The FDA will review the vaccine for approval, and the breakthrough therapy designation could expedite the process.
Importance 40.0 Sentiment 60.0
per
Georgina Long
As principal investigator, Long called the results a landmark moment for melanoma treatment, lending credibility to the findings.
Importance 40.0 Sentiment 60.0
per
Dean Y. Li
As President of Merck Research Laboratories, Li commented on the potential of adjuvant therapy, supporting the scientific rationale.
Importance 40.0 Sentiment 60.0
cnt
United States
The US is the primary market for the vaccine, with regulatory approval and patient access being key.
Importance 30.0 Sentiment 60.0
per
List of EastEnders characters introduced in 1999
As head of oncology early development at Merck, Healy explained the vaccine's mechanism and manufacturing process, providing technical insight.
Importance 30.0 Sentiment 55.0
per
Jedd Wolchok
As a melanoma expert, Wolchok commented on the significance of the trial for cancer immunotherapy, adding expert validation.
Importance 30.0 Sentiment 55.0
per
Daniel Sullivan
As director of the Center for Melanoma, Sullivan called the results a big deal for the field, highlighting potential broader impact.
Importance 30.0 Sentiment 55.0
per
Julie Gralow
As chief medical officer of ASCO, Gralow described the results as a monumental leap forward, validating mRNA technology.
Importance 30.0 Sentiment 55.0
stock
Roche
Roche is developing a similar personalized mRNA cancer vaccine, and the positive results validate the approach, potentially benefiting its pipeline.
Importance 30.0 Sentiment 60.0
+ 48 more entities View on Dashboard
Relationships
Moderna related ↔ Merck & Co.
Moderna co-developer ↔ Merck Group Moderna co-develops personalized mRNA cancer vaccines, including Intismeran, with Merck Group, leveraging its mRNA platf
Moderna related ↔ Stéphane Bancel
Moderna related ↔ United States — Food and Drug Administration
Moderna related ↔ Dean Y. Li
Moderna related ↔ United States
Merck & Co. related ↔ Merck Group
Merck & Co. related ↔ United States — Food and Drug Administration
Merck & Co. related ↔ United States
Merck Group related ↔ Stéphane Bancel
Merck Group related ↔ United States — Food and Drug Administration
Merck Group related ↔ United States
Stéphane Bancel related ↔ Dean Y. Li
United States — Food and Drug Administration related ↔ United States
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.